Lv51
1240 积分 2023-11-06 加入
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
2小时前
待确认
Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer
5个月前
已完结
Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration
6个月前
已完结
Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors
6个月前
已完结
Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma
6个月前
已完结
The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer
7个月前
已完结
New therapeutic target molecules for gastric and gastroesophageal junction cancer
8个月前
已完结
A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function
9个月前
已完结
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma
9个月前
已完结
The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era
11个月前
已完结
皖公网安备34019202002308
